|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of
1 Anaesthesiology
2 Pharmacology, Vanderbilt University, School of Medicine, Nashville, TN 37232, USA
Upon prolonged depolarizations, voltage-dependent Na+ channels open and subsequently inactivate, occupying fast and slow inactivated conformational states. Like C-type inactivation in K+ channels, slow inactivation is thought to be accompanied by rearrangement of the channel pore. Cysteine-labelling studies have shown that lidocaine, a local anaesthetic (LA) that elicits depolarization-dependent (use-dependent) Na+ channel block, does not slow recovery from fast inactivation, but modulates the kinetics of slow inactivated states. While these observations suggest LA-induced stabilization of slow inactivation could be partly responsible for use dependence, a more stringent test would require that slow inactivation gating track the distinct use-dependent kinetic properties of diverse LA compounds, such as lidocaine and bupivacaine. For this purpose, we assayed the slow inactivation-dependent accessibility of cysteines engineered into domain III, P-segment (µ1: F1236C, K1237C) to sulfhydryl (MTSEA) modification using a high-speed solution exchange system. As expected, we found that bupivacaine, like lidocaine, protected cysteine residues from MTSEA modification in a depolarization-dependent manner. However, under pulse-train conditions where bupivacaine block of Na+ channels was extensive (due to ultra-slow recovery), but lidocaine block of Na+ channels was not, P-segment cysteines were protected from MTSEA modification. Here we show that conformational changes associated with slow inactivation track the vastly different rates of recovery from use-dependent block for bupivacaine and lidocaine. Our findings suggest that LA compounds may produce their kinetically distinct voltage-dependent behaviour by modulating slow inactivation gating to varying degrees.
(Received 17 December 2004;
accepted after revision 24 January 2005;
first published online 27 January 2005)
Corresponding author P. C. Viswanathan: 560, Preston Research Building, 2220 Pierce Avenue, Vanderbilt University School of Medicine, Nashville, TN 37232-6602, USA. Email: prakash.viswanathan{at}vanderbilt.edu
This article has been cited by other articles:
![]() |
P. L. Sheets, C. Heers, T. Stoehr, and T. R. Cummins Differential Block of Sensory Neuronal Voltage-Gated Sodium Channels by Lacosamide [(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide], Lidocaine, and Carbamazepine J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 89 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Ouyang, T.-Y. Jih, T.-T. Zhang, A. M. Correa, and H. C. Hemmings Jr. Isoflurane Inhibits NaChBac, a Prokaryotic Voltage-Gated Sodium Channel J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1076 - 1083. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Clancy, Z. I. Zhu, and Y. Rudy Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H66 - H75. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |